Clinical Trial

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

Study acronym: OliGRAIL
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-02-18; most recent amendment 2025-09-12.
Status change: Not Yet Recruiting → Recruiting 2025-05-07
Trial Details
NCT Number NCT06840782
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Enrollment 124 participants
Start Date 2025-09-09
Primary Completion 2030-02 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2025-09-15